Folate-based thymidylate synthase inhibitors in cancer chemotherapy

Anti-Cancer Drugs

Volumn 8, Issue 1, 1997, Pages 3-16

  Takemura, Yuzuru ^a   Jackman, Ann L ^b  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

cancer chemotherapy; colorectal cancer; folate based thymidylate synthase inhibitor; polyglutamation; resistance mechanisms

Indexed keywords

10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; 2 [5 [[(1,2 DIHYDRO 3 METHYL 1 OXOBENZO[F]QUINAZOLIN 9 YL)METHYL]AMINO] 1 OXO 2 ISOINDOLINYL]GLUTARIC ACID; 2 DEAMINO 2 METHYL 10 PROPARGYL 5,8 DIDEAZAFOLIC ACID; ENZYME INHIBITOR; FLUOROURACIL; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; METESIND GLUCURONATE; NOLATREXED; PEMETREXED; PLEVITREXED; RALTITREXED; THYMIDYLATE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; ZM 249148;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; COLORECTAL CANCER; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; FOLIC ACID; HUMANS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; THYMIDYLATE SYNTHASE;

EID: 0031052281     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199701000-00001     Document Type: Review

References (115)

1. Bertino JR, Mini E, Sobrero A, et al. Methotrexate resistant cells as targets for selective chemotherapy. Adv Enzyme Regul 1986; 24: 3-11.
2. Bertino JR, Li WW, Lin J, et al. Enzymes of the thymidylate cycle as targets for chemotherapeutic agents: mechanisms of resistance. Mount Sinai J Med 1992; 59: 391-5.
3. Borsa J, Whitmore, GF. Cell killing studies on the mode of action of methotrexate on L-cells in vitro. Cancer Res 1969; 29: 737-44.
4. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, eds. Cancer chemotherapy: principles and practice. Philadelphia: Lippincott 1990: 180-224.
5. Reichard P, Sköld O, Klein G, Revesz L, Magnusson PH. Studies on resistance against 5-fluorouracil. Cancer Res 1962; 22: 235-43.
6. Kasbekar DK, Greenberg DM. Studies on tumor resistance to 5-fluorouracil. Cancer Res 1963; 23: 818-24.
7. Harrap KR, Jackson RC. Biochemical mechanisms of resistance to antimetabolites. In: Schabel FM, ed. Fundamentals in cancer chemotherapy: antibiotics and chemotherapy. Basel: Karger 1978; 23: 228-37.
8. Mulkins MA, Heidelberger C. Biochemical characterization of fluoropyrimidine-resistant murine leukemic cell lines. Cancer Res 1982; 42: 965-73.
9. Jackman AL, Jones TR, Calvert AH. Thymidylate synthase inhibitors: experimental and clinical aspects. In: Muggia FM, ed. Experimental and clinical progress in cancer chemotherapy. Boston: Martinus Nijhoff 1985: 155-210.
10. Jones TR, Calver AH, Jackman AL, Brown SJ, Jones M, Harrap KR. A potent antitumor quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Eur J Cancer 1981; 17: 11-9.
11. 10-propargyl-5,8-dideazafolic acid (CB3717). Cancer Chemother Pharmacol 1985; 14: 265-71.
12. 10-propargyl-5,8-dideazafolic acid, CB3717. J Clin Oncol 1986; 4: 1245-52.
13. Jones TR, Thornton TJ, Flinn A, Jackman AL, Newell DR, Calvert AH. Quinazoline antifolates inhibiting thymidylate synthase: 2-desamino derivatives with enhanced solubility and potency. J Med Chem 1989; 32: 847-52.
14. Marsham PR, Chambers P, Hayter AJ, et al. Quinazoline antifolate thymidylate synthase inhibitors: nitrogen, oxygen, sulfur and chlorine substituents in the C2 position. J Med Chem 1989; 32: 569-75.
15. 10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res 1990; 50: 5212-8.
16. Hughes LR, Jackman AL, Oldfield J, et al. Quinazoline antifolate thymidylate synthase inhibitors: alkyl, substituted alkyl, and aryl substituents in the C2 position. J Med Chem 1990; 33: 3060-7.
17. 10-propargyl-5,8-dideazafolic acid (ICI 198583), Biochem Pharmacol 1991; 42: 1885-95.
18. Marsham PR, Hughes LR, Jackman AL, et al. Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. J Med Chem 1991; 34: 1594-605.
19. Jackman AL, Kimbell R, Brown M, Brunton L, Boyle FT. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anti-Cancer Drug Des 1995; 10: 555-72.
20. Jackman AL, Kimbell R, Brown M, et al. Quinazoline-based thymidylate synthase inhibitors: relationship between structural modifications and polyglutamation. Anti-Cancer Drug Des 1995; 10: 573-89.
21. Jackman AL, Taylor GA, Bishop JA, et al. Biochemical aspects of a new thymidylate synthase inhibitor, D1694. Proc Am Ass Cancer Res 1990; 31: 342 (abstr 2023).
22. Jodrell DI, Newell DR, Calvete JA, Stephens TC, Calvert AH. Pharmacokinetic and toxicity studies with the novel quinazoline thymidylate synthase inhibitor, ICI D1694. Proc Am Ass Cancer Res 1990; 31: 341 (abstr 2021).
23. Stephens TC, Calvete JA, Janes D, et al. Antitumor activity of new thymidylate synthase (TS) inhibitor, D1694. Proc Am Ass Cancer Res 1990: 31: 342 (abstr 2025).
24. Jackman AL, Taylor GA, Gibson W, et al. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study. Cancer Res 1991; 51: 5579-86.
25. Cunningham D, Zalcberg J, Smith I, et al. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumor activity in a range of solid tumors. Ann Oncol 1996; 7: 179-82.
26. Cunningham D, Zalcberg JR, Rath U, et al. 'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. Eur J Cancer 1995; 31A: 1945-54.
27. Seitz JF, Cunningham D, Rath U, et al. Final results and survival data of a large randomized trial of 'Tomudex' in advanced colorectal cancer (ACC) confirm comparable efficacy to 5-fluorouracil plus leucovorin (5-FU + LV). Proc Am Soc Clin Oncol 1996; 15: 201 (abstr 446).
28. Diddens H, Niethammer D, Jackson RC. Patterns of cross-resistance to the antifolate drugs trimetrexate, metoprine, homofolate, and CB3717 in human lymphoma and osteosarcoma cells resistant to methotrexate. Cancer Res 1983; 43: 5286-92.
29. Jackson RC, Jackman AL, Calvert AH. Biochemical effects of a quinazoline inhibitor of thymidylate synthetase, CB3717, on human lymphoblastoid cells. Biochem Pharmacol 1983; 32: 3783-90.
30. 10-propargyl-5,8-dideazafolate and its polyglutamates against human dihydrofolate reductase, human thymidylate synthetase and KB cells containing different levels of dihydrofolate reductase. Cancer Res 1985; 45: 598-600.
31. Jackman AL, Taylor GA, Calvert AH, Harrap KR. Modulation of antimetabolite effects: effects of thymidine on the efficacy of the quinazoline-based thymidylate synthetase inhibitor, CB3717. Biochem Pbarmacol 1984; 33: 3269-75.
32. 10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. Cancer Res 1992; 52: 1137-43.
33. Kobayashi H, Takemura Y, Miyachi H, Skelton L, Jackman AL. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors. Jpm J Cancer Res 1995; 86: 1014-8.
34. Takemura Y, Kobayashi H, Miyachi H, Gibson W, Kimbell R, Jackman AL. Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs. Jpn J Cancer Res 1996; 87: 773-80.
35. Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. Eur J Cancer 1995; 31A: 1277-82.
36. 10-propargyl-5,8-dideazafolic acid (CB3717): inhibitory effects on human leukemia cell lines resistant to methotrexate or trimetrexate. Mount Sinai J Med 1992; 59: 419-24.
37. Jansen G, Schornagel JH, Westerhof GR, Rijksen G, Newell DR, Jackman AL. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Cancer Res 1990; 50: 7544-8.
38. 10-propargyl-5,8-dideazafolic acid resistant human leukemia MOLT-3 cell lines developed in pteroylglutamic acid, but not in leucovorin. J Cancer Res Clin Oncol 1996; 122: 659-64.
39. Takemura Y, Kobayashi H, Gibson W, Kimbell R, Miyachi H, Jackman AL. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells. Int J Cancer 1996; 66: 29-36.
40. Chabner BA, Allegra CJ, Curt GA, et al. Polyglutamation of methotrexate. J Clin Invest 1985; 76: 907-12.
41. Galivan J. Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 1980; 17: 105-10.
42. Ward WHJ, Kimbell R, Jackman AL. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol 1992; 43: 2029-31.
43. 10-substituted-5,8-dideazafolates. Adv Enzyme Regul 1991; 31: 13-27.
44. McGuire JJ, Hsieh P, Coward JK, Bertino JR. Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products. J Biol Chem 1980; 255: 5776-88.
45. George S, Cichowicz DJ, Shane B. Mammalian folylpoly-γ-glutamate synthetase. 3 Specificity for folate analogues. Biochemistry 1987; 26: 522-9.
46. Clarke L, Waxman DJ. Human liver folylpolyglutamate synthetase: biochemical characterization and interactions with folates and folate antagonists. Arch Biochem Biophys 1987; 256: 585-96.
47. Habeck LL, Mendelsohn LG, Shih C, et al. Substrate specificity of mammalian folylpolyglutamate synthetase for 5,10-dideazatetrahydrofolate analogs. Mol Pharmacol 1995; 48: 326-33.
48. 10-propargyl-5,8-dideazafolic acid (CB3717) polyglutamates in L1210 cells in vitro. Biochem Pharmacol 1988; 37: 4047-54.
49. Gibson W, Bisset GMF, Marsham PR, Kelland LR, Judson IR, Jackman AL. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICT D1694, in mouse and human cultured cells. Biochem Pharmacol 1993; 45: 863-9.
50. Jackman AL, Kelland LR, Kimbell R, et al. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer 1995; 71: 914-24.
51. 10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies. Cancer Res 1986; 46: 2810-5.
52. Takemura Y, Gibson W, Kimbell R, Kobayashi H, Miyachi H, Jackman AL. Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug. J Cancer Res Clin Oncol 1996; 122: 109-17.
53. Jackman AL, Gibson W. Polyglutamation of the thymidylate synthase inhibitor, ZD1694 (Tomudex), in normal mouse tissues. Proc Am Ass Cancer Res 1995; 36: 377 (abstr 2245).
54. McCloskey DE, McGuire JJ, Russell CA, et al. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines. J Biol Chem 1991; 266: 6181-7.
55. Barakat RR, Lovelace CIP, Li WW, Bertino JR. Decreased formation of methotrexate (MTX) polyglutamates in cervical squamous cell carcinoma (SCC) cell lines intrinsically resistant to MTX is associated with decreased expression of folylpolyglutamyl synthetase (FPGS). Proc Am Ass Cancer Res 1994; 35: 305 (abstr 1815).
56. Lu K, Yin MB, McGuire JJ, Bonmassar E, Rustum YM. Mechanisms of resistance to N-[5-[N-(3,4-dihydro-2-methy1-4-oxoquinazolin-6-ylmethyl)-N-methylamino]-2- thenoyl]-L-glutamic acid (ZD1694), a folate-based thymidylate synthase inhibitor, in the HCT-8 human ileocecal adenocarcinoma cell line. Biochem Pharmacol 1995; 50: 391-8.
57. Li WW, Waltham M, Tong W, Schweitzer BI, Bertino JR. Increased activity of γ-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate. Adv Exp Med Biol 1993; 338: 635-8.
58. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 1993; 53: 2227-30.
59. 10-propargyl-5,8-dideazafolic acid (CB3717). J Cancer Res Clin Oncol 1991; 117: 519-25.
60. Sotos GA, Grogan L, Allegra CJ. Preclinical and clinical aspects of biomodulation of 5-fluorouracil. Cancer Treat Rev 1994; 20: 11-49.
61. Pizzorno G, Mini E, Coronnello M, et al. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. Cancer Res 1988; 48: 2149-55.
62. Baskin F, Carlin SC, Kraus P, Friedkin M, Rosenberg RN. Experimental chemotherapy of neuroblastoma. Mol Pharmacol 1975; 11: 105-17.
63. Priest DG, Ledford BE, Doig MT. Increased thymidylate synthetase in 5-fluorodeoxyuridine-resistant cultured hepatoma cells. Biochem Pharmacol 1980; 29: 1549-53.
64. Rossana C, Rao LG, Johnson LF. Thymiclylate synthase overproduction in 5-fluorodeoxyuridine-resistant mouse fibroblasts. Mol Cell Biol 1982; 2: 1118-25.
65. Berger SH, Jenh CH, Johnson LF, Berger FG. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985; 28: 461-7.
66. Jenh CH, Geyer PK, Baskin F, Johnson LF. Thymidylate synthase gene amplification in fluorodeoxyuridine-resistant mouse cell lines. Mol Pharmacol 1985; 28: 80-5.
67. Clark JL, Berger SH, Mittelman A, Berger FG. Thymidylate synthase gene amplification in a colon tumour resistant to fluoropyrimidine chemotherapy. Cancer Treat Rep 1987; 71: 261-5.
68. Ohnuma T, Lo RJ, Scanlon KJ, et al. Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro. Cancer Res 1985; 45: 1815-22.
69. Freemantle SJ, Jackman AL, Kelland LR, Calvert AH, Lunec J. Molecular characterisation of two cell lines selected for resistance to the folate-based thymidylate synthase inhibitor, ZD1694. Br J Cancer 1995; 71: 925-30.
70. Roy K, Egan MG, Sirlin S, Sirotnak FM. Posttranscriptionally mediated decreases in folylpolyglutamate synthetase gene expression in edatrexate resistant L1210 cells. Proc Am Ass Cancer Res 1996; 37: 383 (abstr 2612).
71. Roy K, Mitsugi K, Sirotnak FM. Organization and alternate splicing of the murine folylpolyglutamate synthetase gene. Proc Am Ass Cancer Res 1996; 37: 383 (abstr 2611).
72. Chen L, Qi H, Korenberg J, Garrow TA, Choi YJ, Shane B. Purification and properties of human cytosolic folylpoly-γ-glutamate synthetase and organization, localization, and differential splicing of its gene. J Biol Chem 1996; 271: 13077-87.
73. Swain SM, Lippman ME, Egan EF, Drake JC, Steinberg SM, Allegra CJ. Fluorouracil and high-dose leucovorin in previously treated patients with metastatic breast cancer. J Clin Oncol 1989; 7: 890-9.
74. Chu E, Zinn S, Boarman D, Allegra CJ. Interaction of γ interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 1990; 50: 5834-40.
75. Chu E, Koeller DM, Casey JL, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991; 88: 8977-81.
76. Chu E, Voeller D, Koeller DM, et al. Identification of an RNA binding site for human thymidylate synthase. Proc Natl Acad Sci USA 1993; 90: 517-21.
77. Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem 1993; 268: 15142-9.
78. Allegra C, Chu E. Strategies designed to inhibit the catalytic activity of thymidylate synthase. Proc Am Ass Cancer Res 1996; 37: 651 (extended abstr).
79. Jodrell DI, Newell DR, Gibson W, Hughes LR, Calvert AH. The pharmacokinetics of the quinazoline antifolate ICI D1694 in mice and rats. Cancer Chemother Pharmacol 1991; 28: 331-8.
80. Jackman AL, Jodrell DI, Gibson W, Stephens TC. ICI D1694, an inhibitor of thymidylate synthase for clinical study. In: Harkness RA, Elion TB, eds. Purine and pyrimidine metabolism in man VII, part A. New York: Plenum Press 1991: 19-23.
81. Stephens TC, Valcaccia BE, Sheader ML, Hughes LR, Jackman AL. The thymidylate synthase inhibitor ICI D1694 is superior to CB3717, 5-fluorouracil and methotrexate against a panel of human tumour xenografts. Proc Am Ass Cancer Res 1991; 32: 328 (abstr 1947).
82. Clarke SJ, Ward J, De Boer M, et al. Phase I study of the new thymidylate synthase inhibitor Tomudex (ZD1694) in patients with advanced malignancy. Ann Oncol 1994; 5 (suppl 5): 132 (abstr 240).
83. Clarke SJ, Hanwell J, De Boer M, et al Phase I trial of ZD1694, a new folate-based thymidylate synthase inhibitor, in patients with solid tumors. J Clin Oncol 1996; 14: 1495-503.
84. Sorensen JM, Jordan E, Grem JL, et al. Phase I trial of ZD1694 (Tomudex), a direct inhibitor of thymidylate synthase. Ann Oncol 1994; 5 (suppl 5): 132 (abstr 241).
85. Smith IE, Spielmann M, Bonneterre J, et al. Tomudex (ZD1694), a new thymidylate synthase inhibitor with antitumour activity in breast cancer. Ann Oncol 1994; 5 (suppl 5): 132 (abstr 242).
86. Pazdur R, Casper ES, Meropol NJ, Fuchs C, Kennealey GT. Phase II trial of Tomudex (ZD1694), a thymidylate synthase inhibitor, in advanced pancreatic cancer. Proc Am Soc Clin Oncol 1994; 13: 207 (abstr 613).
87. Burris III H, Von Hoff D, Bowen K, et al. A phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Ann Oncol 1994; 5 (suppl 5): 133 (abstr 244).
88. Gore M, Earl H, Cassidy J, Tattersal M, Mansi J, Azab M. Phase II study of Tomudex (ZD1694) in refractory ovarian cancer. Ann Oncol 1994; 5 (suppl 5): 133 (abstr 245).
89. Zalcberg JR, Cunningham D, Van Cutsem E, et al. ZD1694: a novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. J Clin Oncol 1996; 14: 716-21.
90. Wardleworth JM, Boyle FT, Barker RJ, et al. ZD9331: the design and synthesis of a novel non-polyglutamatable TS inhibitor. Ann Oncol 1994; 5 (suppl 5): 134 (abstr 247).
91. Jackman AL, Aherne GW, Kimbell R, et al. ZD9331, a non-polyglutamatable quinazoline thymidylate synthase (TS) inhibitor. Proc Am Ass Cancer Res 1994; 35: 301 (abstr 1791).
92. Boyle FT, Wardleworth JM, Hennequin LF, et al. ZD9331 - design of a novel non-polyglutamatable quinazoline-based inhibitor of thymidylate synthase (TS). Proc Am Ass Cancer Res 1994; 35: 305 (abstr 1817).
93. Stephens TC, Smith MN, McCloskey ML, Boyle FT. ZD9331, a novel non-polyglutamated thymidylate synthase (TS) inhibitor: in vivo antitumor efficacy and toxicity to normal murine tissues. Proc Am Ass Cancer Res 1994; 35: 305 (abstr 1816).
94. Jackman AL, Kimbell R, Brown M, et al. The antitumor activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol 1995; 370: 185-8.
95. Jackman AL, Kimbell R, Brunton L, Aherne GW, Walton M, Kelland L. Activity of ZD1694 and ZD9331 in human colon and ovarian tumour cell lines. Proc Am Ass Cancer Res 1996; 37: 381 (abstr 2604).
96. Duch DS, Banks S, Dev IK, et al. Biochemical and cellular pharmacology of 1843U89, a novel benzoquinazoline inhibitor of thymidylate synthase. Cancer Res 1993; 53: 810-8.
97. Smith GK, Amyx H, Bigley JW, et al. 1843U89, a non-competitive thymidylate synthase inhibitor with novel potential for enhanced antitumor selectivity via combination with folic acid. Proc Am Ass Cancer Res 1996; 37: 651-2 (extended abstr).
98. Rinaldi DA, Burris HA, Dorr FA, et al. Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 1995; 13: 2842-50.
99. Schultz RM, Andis SL, Bewley JR, et at. Antitumor activity of the multitargeted antifolate LY231514. Proc Am Ass Cancer Res 1996; 37: 380 (abstr 2597).
100. Rinaldi DA, Burris HA, Dorr FA, et al. A phase I evaluation of LY231514, a novel multitargeted antifolate, administered every 21 days. Proc Am Soc Clin Oncol 1996; 15: 489 (abstr 1559).
101. Appelt K, Bacquet RJ, Bartlett CA, et al. Design of enzyme inhibitors using iterative protein crystallographic analysis. J Med Chem 1991; 34: 1925-34.
102. Varney MD, Marzone GHP, Palmer CL, et al. Crystalstructure-based design and synthesis of benzo[d]indole-containing inhibitors of thymidylate synthase. J Med Chem 1992; 35: 663-76.
103. Reich SH, Fuhry MAM, Nguyen D, et al. Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysis. J Med Chem 1992; 35: 847-58.
104. Jackson RC, Johnston AL, Shetty BV, Varney MD, Webber SE. Molecular design of thymidylate synthase inhibitors. Proc Am Ass Cancer Res 1993: 34: 566-7 (extended abstr).
105. Webber S, Bartlett C, Boritzki TJ, et al. AG337, a novel lipophilic thymidylate synthase inhibitor: in vitro and in vivo preclinical studies. Cancer Chemother Pharmacol 1996; 37: 509-17.
106. O'Connor BM, Webber S, Jackson RC, Galivan J, Rhee MS. Biological activity of a novel rationally designed lipophilic thymidylate synthase inhibitor. Cancer Chemother Pharmacol 1994; 34: 225-9.
107. Calvete JA, Balmanno K, Taylor GA, et al. Preclinical and clinical studies of prolonged administration of the novel thymidylate synthase inhibitor, AG337. Proc Am Ass Cancer Res 1994; 35: 306 (abstr 1821).
108. Rafi I, Taylor GA, Calvete JA, et al. A phase I clinical study of the novel antifolate AG337 given by a 5 day continuous infusion. Proc Am Ass Cancer Res 1995; 36: 240 (abstr 1433).
109. Clendeninn NJ, Collier MA, Johnston AL, et al. Thymitaq™ (AG337): a novel thymidylate synthase inhibitor with clinical activity in solid tumors. Proc Am Ass Cancer Res 1996; 37: 171 (abstr 1176).
110. Loh KK, Cohn A, Kelly K, et al. Phase II trials of Thymitaq™ (AG337) in six solid tumor diseases. Proc Am Soc Clin Oncol 1996; 15: 183 (abstr 385).
111. Clendeninn NJ, Peterkin JJ, Webber S, et al. AG-331, a 'non-classical' lipophilic thymidylate synthase inhibitor for the treatment of solid tumors. Ann Oncol 1994; 5 (suppl 5): 133 (abstr 246).
112. Koda RT, Leichman L, Webber S, et al. Pharmacokinetics of AG-331 following single escalating i.v. doses in patients with refractory solid tumors. Proc Am Ass Cancer Res 1994; 35: 432 (abstr 2578).
113. Parimoo D, Muggia F. Leichman CG, et al. Phase I and pharmacokinetic (PK) study of AG331, a non-classical thymidylate synthase (TS) inhibitor. Proc Am Ass Cancer Res 1996; 37: 184 (abstr 1257).
114. Calvete JA, Balmanno K, Rafi I, et al. Pre-clinical and clinical studies of the novel thymidylate synthase inhibitor, AG337, given by oral administration. Proc Am Ass Cancer Res 1995; 36: 380 (abstr 2262).
115. Jodrell D, Bowman A, Rye R, et al. A Phase I, pharmacokinetic/pharmacodynamic study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (AG337) administered orally, 6 hourly for 10 days. Proc Am Ass Cancer Res 1996; 37: 184 (abstr 1256).